470 related articles for article (PubMed ID: 25455737)
1. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
[TBL] [Abstract][Full Text] [Related]
2. Pituitary apoplexy after leuprolide.
Davis A; Goel S; Picolos M; Wang M; Lavis V
Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
[TBL] [Abstract][Full Text] [Related]
3. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
[TBL] [Abstract][Full Text] [Related]
4. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
Morsi A; Jamal S; Silverberg JD
Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
[TBL] [Abstract][Full Text] [Related]
5. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
Hernandez Morin N; Huet D; Hautecouverture M
Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
7. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
[TBL] [Abstract][Full Text] [Related]
8. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
Reznik Y; Chapon F; Lahlou N; Deboucher N; Mahoudeau J
J Endocrinol Invest; 1997 Oct; 20(9):566-8. PubMed ID: 9413812
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
10. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
Tanios G; Mungo NA; Kapila A; Bajaj K
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710301
[TBL] [Abstract][Full Text] [Related]
11. Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment.
Elshimy G; Raj R; Jacob A; Correa R
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256375
[TBL] [Abstract][Full Text] [Related]
12. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
Guerra Y; Lacuesta E; Marquez F; Raksin PB; Utset M; Fogelfeld L
Pituitary; 2010; 13(1):54-9. PubMed ID: 19842040
[TBL] [Abstract][Full Text] [Related]
13. A Case of Pituitary Apoplexy Following Leuprolide Injection for Prostate Cancer.
Kim KW; Chee S; Sunkara N; Baker MH
R I Med J (2013); 2024 Feb; 107(2):7-9. PubMed ID: 38285742
[TBL] [Abstract][Full Text] [Related]
14. Pituitary Apoplexy After Initial Leuprolide Injection.
Fabiano AJ; George S
World Neurosurg; 2016 Nov; 95():616.e7-616.e9. PubMed ID: 27586180
[TBL] [Abstract][Full Text] [Related]
15. Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone.
Masson EA; Atkin SL; Diver M; White MC
Clin Endocrinol (Oxf); 1993 Jan; 38(1):109-10. PubMed ID: 8435878
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature.
Hands KE; Alvarez A; Bruder JM
Endocr Pract; 2007 Oct; 13(6):642-6. PubMed ID: 17954421
[TBL] [Abstract][Full Text] [Related]
17. The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.
Babbo A; Kalapurakal GT; Liu B; Bajramovic S; Chandler JP; Garnett J; Kalapurakal JA
Int Urol Nephrol; 2014 Sep; 46(9):1775-8. PubMed ID: 24705727
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
19. Gonadotropin-releasing hormone-induced partial empty sella clinically mimicking pituitary apoplexy in a woman with a suspected non-secreting macroadenoma.
Foppiani L; Piredda S; Guido R; Spaziante R; Giusti M
J Endocrinol Invest; 2000 Feb; 23(2):118-21. PubMed ID: 10800766
[TBL] [Abstract][Full Text] [Related]
20. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
